Sign inJoin waitlistJoin the waitlist

Faisal Cheema

Faculty, Malignant Hematology · Medical Oncology at KP Santa Clara

Credentials: · · · · · · · ·

History

Medical Oncology at KP Santa Clara
Present

Geriatric Medicine
Baylor College of Medicine
2009–2010
Stanford University School of Medicine
2008–2009
Hematology and Oncology
LSU Health Sciences Center
2007–2008
Hematology and Medical Oncology
Baylor College of Medicine
2004–2007
Internal Medicine
Jewish Hospital of Cincinnati
2001–2004
Dow Medical College
1997–2001

Research

Novel approaches to perioperative assessment and intervention may improve long-term outcomes after colorectal cancer resection in older adults
Annals of Surgery · 2011 · First of 6 authors · 65 citations
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS),…
Leukemia & lymphoma/Leukemia and lymphoma · 2023 · 15 citations
Double hit lymphoma - a case of unusual response after sequential aggressive chemotherapy and review of the literature
Case report · Clinical Medicine Insights Case Reports · 2014 · First of 4 authors · 3 citations

Aanand Naik
1 paper
Adam Asch
1 paper
DA
Daniel Albo
1 paper
DB
David Berger
1 paper
Deborah Gho
1 paper
Geoffrey Uy
1 paper
George Taffet
1 paper
Gerhard Hildebrandt
1 paper
Harry Erba
1 paper
Jerald Radich
1 paper
JL
Jijun Liu
1 paper
KS
Kendra Sweet
1 paper

Clinical trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029